Contineum prices upsized $90M public offering at $12.25/share; net proceeds ~$84.2M

Contineum Therapeutics, Inc.

7,346,938 shares of Class A common stock sold at $12.25 per share, up from planned $75M.
Underwriters have a 30-day option to purchase up to 1,102,040 additional shares.
Net proceeds estimated at $84.2M after underwriting discounts and expenses.
Joint book-runners: Goldman Sachs, Leerink Partners, Stifel, RBC, William Blair; Jones as manager.
Offering closed December 15, 2025, with proceeds for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Contineum Therapeutics, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters (effective 2025-12-11).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters
Effective: 2025-12-11

Exact text from the filing

On December 11, 2025, Contineum Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters named in the Underwriting Agreement (the “Underwriters”), relating to the sale of 7,346,938 shares (the “Shares”) of the Company’s Class A common stock

View on SEC.gov

Browse all material agreements →

Contineum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-037842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.